公开(公告)号：US10221242B2

公开(公告)日：2019-03-05

申请号：US15402807

申请日：2017-01-10

Applicant: PFIZER INC.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Barbra Johnson Sasu

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvIII and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates. The invention further relates to therapeutic methods for use of these antibodies and antibody conjugates for the treatment of EGFRvIII-mediated pathologies, including cancer such as glioblastoma.

公开(公告)号：US20220227874A1

公开(公告)日：2022-07-21

申请号：US17586321

申请日：2022-01-27

Applicant: Pfizer Inc.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Mathilde Brunnhilde Dusseaux ,  Julianne Smith ,  Barbra Johnson Sasu

IPC: C07K16/28 ,  C07K14/47 ,  C07K14/725

Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.

公开(公告)号：US11267892B2

公开(公告)日：2022-03-08

申请号：US16255348

申请日：2019-01-23

Applicant: Pfizer Inc.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Mathilde Brunnhilde Dusseaux ,  Julianne Smith ,  Barbra Johnson Sasu

IPC: A61K35/17 ,  C12N9/64 ,  A61K31/436 ,  C07K16/28 ,  C07K14/47 ,  C07K14/725 ,  A61K38/00 ,  A61K39/00

Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.

公开(公告)号：US11279764B2

公开(公告)日：2022-03-22

申请号：US16163243

申请日：2018-10-17

Applicant: Pfizer Inc.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Barbra Johnson Sasu

IPC: C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvIII and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates. The invention further relates to therapeutic methods for use of these antibodies and antibody conjugates for the treatment of EGFRvIII-mediated pathologies, including cancer such as glioblastoma.

公开(公告)号：US10259876B2

公开(公告)日：2019-04-16

申请号：US15402760

申请日：2017-01-10

Applicant: PFIZER INC.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Mathilde Brunnhilde Dusseaux ,  Julianne Smith ,  Barbra Johnson Sasu

IPC: A61K35/17 ,  C12N9/64 ,  A61K31/436 ,  C12N15/62 ,  C07K16/28 ,  C07K14/725 ,  C07K14/47 ,  A61K39/00 ,  A61K38/00

Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.